arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

BIOMARIN PHARMACEUTICAL INC

BMRN
$63.38 ▼ -0.67 (-1.04%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
72 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Neutral
auto_awesome

Analytical Summary

BIOMARIN PHARMACEUTICAL INC shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $12.3B
Dividend Yield
Revenue Growth 19.9%
Op. Margin 11.2%
ROIC 0.8%
FCF / Share $0.72
Trailing P/E 275.6x
Price / Book 1.9x
FCF Yield 1.1%
Debt / Equity 0.66
info Valuation on last close. End-of-day price, Sep 22, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$989.71M
↑ +19.9%
Net Income Profit after all expenses
$44.76M
↓ -81.4%
Operating Margin Operating profit as % of sales
11.2%
↓ -33.8% 63th
FCF / Share Free cash flow per share
$0.72
↓ -30.6%
Long-Term Debt Long-term obligations
$4.19B
↑ +192.7%

Health Breakdown

Profitability
71
Returns
55
Financial Health
94
Cash Quality
87

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 19 years · 72 quarters